Ask about this productRelated genes to: ZNF610 antibody
- Gene:
- ZNF610 NIH gene
- Name:
- zinc finger protein 610
- Previous symbol:
- -
- Synonyms:
- FLJ36040
- Chromosome:
- 19q13.41
- Locus Type:
- gene with protein product
- Date approved:
- 2004-03-29
- Date modifiied:
- 2014-11-19
Related products to: ZNF610 antibody
Related articles to: ZNF610 antibody
- Despite therapeutic advances, atherosclerosis remains a major global health challenge. Most current treatments target systemic risk factors rather than the diseased vascular wall. Our previous work identified genistein, a soy isoflavone, as a cannabinoid receptor 1 (CB1) antagonist capable of suppressing CB1-mediated vascular inflammation and atherosclerosis. However, its poor water solubility and low oral bioavailability limit clinical application. - Source: PubMed
Publication date: 2026/01/21
Chung Dai-JungChen Shao-PengLiu Wei-HsuanLiu Chia-YuSu Nan-WeiHsu ChenTsai Hsin-YaYang Kai-ChienWu Cho-KaiLin Sheng-WeiShie Jiun-JieZhao Ming-TaoWei Tzu-Tang - A range of cancer cells are significantly inhibited by FTY720. It is unknown, nevertheless, how FTY720 influences the onset of non-small cell lung cancer (NSCLC). Using bioinformatics techniques, we analyzed and the possible molecular mechanisms and targets of FTY720 for the treatment of NSCLC. - Source: PubMed
Publication date: 2025/09/23
Han MengyuanHailati SendaerDilimulati DilihumaBaishan AlharAikebaier AlifeiyeZhou Wenting - Zinc finger proteins (ZNFs) play a significant role in the initiation and progression of tumors. Nevertheless, the specific contribution of ZNF610 to lung adenocarcinoma (LUAD) remains poorly understood. This study sought is to elucidate the role of ZNF610 in LUAD. Transcript data of LUAD were obtained from The Cancer Genome Atlas Program (TCGA) database and processed via R program. The expression of ZNF610 was assessed in various cell lines. To compare the proliferative capacity of cells with or without ZNF610 silencing, CCK8, cell colony formation assay, and Celigo label-free cell counting assay were employed. Furthermore, transwell migration and invasion assays were conducted to evaluate the migratory and invasive abilities of the cells. The expression levels of genes and proteins were assessed using quantitative real-time polymerase chain reaction (qRT-PCR) and western blot techniques. In different LUAD cells, the expression level of ZNF610 was found to be significantly higher in LUAD cells compared to MRC-5 and BASE-2B cells. Moreover, the silencing of ZNF610 resulted in a decrease in cell proliferation and migration abilities. Additionally, the apoptosis rate of cells increased upon silencing ZNF610. Notably, the proportion of cells in the G0/G1 phase increased, while the proportion of cells in the S phase decreased following ZNF610 silencing. Finally, β-catenin and snail were identified as downstream targets of ZNF610 in cells. Our findings suggest that silencing ZNF610 could inhibit LUAD cell proliferation and migration, possibly through the downregulation of β-catenin and snail. - Source: PubMed
Shi YeCui WeimingXi LeiLiu FengLiu ZichengJiang JieLiu ZhengchengCao Hui - Prostate cancer (PC) is one of the most common cancers among men worldwide, and advanced PCs, such as locally advanced PC (LAPC) and castration-resistant PC (CRPC), present the greatest challenges in clinical management. Current indicators have limited capacity to predict the disease course; therefore, better prognostic markers are greatly needed. In this study, we performed a bioinformatic analysis of The Cancer Genome Atlas (TCGA) datasets, including RNA-Seq data from the prostate adenocarcinoma (PRAD; = 55) and West Coast Dream Team - metastatic CRPC (WCDT-MCRPC; = 84) projects, to evaluate the transcriptome changes associated with progression-free survival (PFS) for LAPC and CRPC, respectively. We identified the genes whose expression was positively/negatively correlated with PFS. In LAPC, the genes with the most significant negative correlations were , , and , and the genes with the most significant positive correlations were , , , , and . In CRPC, the most significant positive correlations were found for , , , and , and the most significant negative correlations were found for , , , , and . In addition, we performed a gene network interaction analysis using STRINGdb, which revealed a significant relationship between genes predominantly involved in the cell cycle and characterized by upregulated expression in early recurrence. Based on the results, we propose several genes that can be used as potential prognostic markers. - Source: PubMed
Publication date: 2021/01/21
Pudova Elena AKrasnov George SKobelyatskaya Anastasiya ASavvateeva Maria VFedorova Maria SPavlov Vladislav SNyushko Kirill MKaprin Andrey DAlekseev Boris YTrofimov Dmitry YSukhikh Gennady TSnezhkina Anastasiya VKudryavtseva Anna V - DNA methylation plays an important role in the etiology and pathogenesis of head and neck squamous cell carcinoma (HNSCC). The current study aimed to identify aberrantly methylated-differentially expressed genes (DEGs) by a comprehensive bioinformatics analysis. In addition, we screened for DEGs affected by DNA methylation modification and further investigated their prognostic values for HNSCC. We included microarray data of DNA methylation (GSE25093 and GSE33202) and gene expression (GSE23036 and GSE58911) from Gene Expression Omnibus. Aberrantly methylated-DEGs were analyzed with R software. The Cancer Genome Atlas (TCGA) RNA sequencing and DNA methylation (Illumina HumanMethylation450) databases were utilized for validation. In total, 27 aberrantly methylated genes accompanied by altered expression were identified. After confirmation by The Cancer Genome Atlas (TCGA) database, 2 hypermethylated-low-expression genes (FAM135B and ZNF610) and 2 hypomethylated-high-expression genes (HOXA9 and DCC) were identified. A receiver operating characteristic (ROC) curve confirmed the diagnostic value of these four methylated genes for HNSCC. Multivariate Cox proportional hazards analysis showed that FAM135B methylation was a favorable independent prognostic biomarker for overall survival of HNSCC patients. - Source: PubMed
Publication date: 2018/08/10
Zhou ChongchangYe MengNi ShuminLi QunYe DongLi JinyunShen ZhisenDeng Hongxia